Plasmid News and Research

RSS

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced today that the Company has entered into an exclusive cGMP manufacturing agreement with VGXI Inc. (VGXI) for the production of interleukin-12 plasmid DNA.

6 Jun 2012

Promega launches novel luciferase more versatile than current bioluminescent enzyme

Promega Corporation announces the launch of a novel luciferase that is smaller, brighter, and more versatile than any current bioluminescent enzyme. These attributes of the NanoLuc Luciferase provide new capabilities in reporter assays with potential in biologically complex applications that require greater sensitivity.

1 Jun 2012

Single test developed that detects all known strains of H5N1

The close collaboration between scientists from the Experimental Therapeutics Centre (ETC) under the Agency for Science and Technology Research (A*STAR) and clinicians from Tan Tock Seng Hospital (TTSH) has enabled the successful development of the most comprehensive and rapid H5N1 bird flu test kit available to date.

29 May 2012

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

Pyromaker can more accurately identify complex genetic mutations

DNA sequencing to detect genetic mutations can aid in the diagnosis and selection of treatment for cancer. Current methods of testing DNA samples, Sanger sequencing and pyrosequencing, occasionally produce complex results that can be difficult or impossible to interpret. Scientists at the Johns Hopkins University School of Medicine have developed a free software program, Pyromaker, that can more accurately identify such complex genetic mutations.

6 Feb 2012

Researchers investigate Avian Pathogenic E. coli strains

Escherichia coli bacteria thrive in the lower intestine of humans and other animals, including birds. Most are vital constituents of the healthy gut flora, but certain forms of E. coli cause a range of diseases in both humans and poultry.

1 Feb 2012

NIH awards DNASU $6.5M grant to expand Protein Structure Initiative-Materials Repository

Arizona State University's Biodesign Institute- is home to a rich trove of biological material. Known as DNASU, this growing storehouse-a sort of genetic Library of Congress-holds over 147,000 plasmids, (circular DNA samples that can be used to produce individual proteins), as well as full genome collections from numerous organisms and proteins associated with many leading human diseases.

21 Oct 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

Genetic analysis of medieval plague skeletons proves the presence of y. pestis bacteria

Genetic analysis of medieval plague skeletons proves the presence of yersinia pestis bacteria. Collaboration between the University of Tübingen and Canadian scientists proves today's plague pathogen has been around at least 600 years.

30 Aug 2011

Sigma introduces CompoZr Targeted Integration Kit – mRosa26

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich Corporation today announced the launch of CompoZr Targeted Integration Kit – mRosa26, which can precisely and rapidly integrate transgenes into the mouse genome at the Rosa26 safe harbor locus.

19 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

Researchers use clever technique to look at in vivo virus-bacterium interactions

Viruses are the most abundant parasites on Earth. Well known viruses, such as the flu virus, attack human hosts, while viruses such as the tobacco mosaic virus infect plant hosts.

2 Jul 2011

BGI releases first complete map of Germany E. coli O104:H4 genome

Building upon previous efforts producing a high-quality de novo genome assemblies of deadly 2011 E. coli O104:H4 outbreak strain, the BGI and their collaborators at the University Medical Centre Hamburg-Eppendorf have now released the first complete map of the genome and plasmids without any assembly gaps.

17 Jun 2011

GeneTex to introduce new Easy-iPSC minicircle DNA vector technology in June

GeneTex, a leading manufacturer of antibodies for research use, is pleased to announce they will be launching several new exciting products in June, including the new Easy-iPSC minicircle DNA vector technology.

9 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

Berkeley Lab researchers aim to create biological circuits for synthetic biology

Taking a page from the book of San Francisco radio legend Scoop Nisker, biologists who find themselves dissatisfied with the microbes nature has provided are going out and making some of their own. Members of the fast-growing "synthetic biology" research community are designing and constructing novel organisms and biologically-inspired systems - or redesigning existing organisms and systems - to solve problems that natural systems cannot.

27 May 2011

NTC, Aldevron partner to manufacture first plasmid DNA-based genetic cosmetic

Nature Technology Corporation "NTC" and Aldevron today announced a joint effort to manufacture the world's first plasmid DNA-based genetic cosmetic for Gene Facelift.

11 May 2011